Comparison between Two Methods of Ovulation Induction: Clomiphene alone and Clomiphene +Tamoxifen in PCOS Patients

Publish Year: 1383
نوع سند: مقاله ژورنالی
زبان: English
View: 379

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJRM-2-2_006

تاریخ نمایه سازی: 16 شهریور 1395

Abstract:

Background: Infertility affects about 10-15% of reproductive-age couples. About half the causes of infertility are female related and approximately 40% of the cases are caused by anovulation, mostlyin PCO women. Objective: This study was conducted to determine and compare the effects of two drug treatmentregimens: higher dose of clomiphene and a combination of lower dose of clomiphene and tamoxifen in treating infertile women with PCO. Materials and Methods: The study was a randomized clinical trial conducted on 100 infertile patients who referred to Yazd-Iran Infertility Clinic between the years 2001-2003. The patientswere selected who had received at least 3 periods of clomiphene, but no pregnancy had occurred.They were randomly divided into two groups. In the first group, clomiphene was increased to 100 mg and the second group 20 mg of tamoxifen was added to 50 mg of clomiphene from day 5-9 ofmenstruation cycle. Infertility duration, duration of medicine used, PCT score, endometrial thickness, ovulation, and pregnancy rate were studied in both groups. Results: Ovulation rate in clomiphene group was 54.9%; Tamoxifen + clomiphene group was73.5% without significant differences in both groups. (PV = 0.053). Positive pregnancy rate in clomiphene group was 39.2%; clomiphene + tamoxifen group was 61.2% (P value < 0.05), whichcould be concluded that pregnancy rate was higher in clomiphene/tamoxifen group than in theclomiphene group. The presence of a dominant follicle in the two treatment groups in women between 18-24 was not significant, but in women between 25-39 years was significant (PV= 0.049)(Table III). Conclusion: The recommendation is to add Tamoxifen to Clomiphene in 35-39 women with 20≤BMI ≤26.99 before the use of gonadotropins treatment in PCOS with or without IUI, because these options have higher risk of multiple pregnancy and ovarian hyperstimulation syndrome

Authors

Mohammad Ghafourzadeh

Shahid Sadoughi Univerisity of Medical Sciences and Health Services of Yazd, Iran.

Mojgan Karimi

Shahid Sadoughi Univerisity of Medical Sciences and Health Services of Yazd, Iran.

Mohammad Ali Karimazadeh

Shahid Sadoughi Univerisity of Medical Sciences and Health Services of Yazd, Iran.

Mahshid Bokai

Shahid Sadoughi Univerisity of Medical Sciences and Health Services of Yazd, Iran.